TaiGen Biopharmaceuticals Holdings Ltd (太景) on Thursday said that its hepatitis C drug, Furaprevir (TG-2349), has secured patent protection in the US until May 2037.
Apart from the US patent on Furaprevir’s solid dispersion formulation, the drug is protected by 98 patents in other major markets, the company said.
The US market for hepatitis C treatment is dominated by Gilead Sciences Inc’s offerings and becoming increasingly saturated, a TaiGen investor relations manager said.
Therefore, a US patent would be beneficial to the market value of TaiGen’s hepatitis C therapy, said the manager, who spoke on condition of anonymity.
Furaprevir, a NS3/4A protease inhibitor, is a component of a combination therapy being developed by a joint venture established by TaiGen and China’s HEC Pharma Co (東陽光藥), which supplies Yimitasvir (DAG-181), the NS 5 protein inhibitor that makes up the other half of the combination.
The combination therapy has begun phase 2 clinical trials in China and recruited about 80 percent of patients required for the study in about three months, the company said, adding that it would take two to three years to make the same progress in Taiwan.
Phase 2 clinical trials are expected to be completed before the end of this year, making TaiGen eligible for a US$5 million milestone payment from its Chinese partner, the company said.
The company plans to start phase 3 trials next year and expects to receive up to US$15 million in milestone payments between 2020 and 2021, it said.
TaiGen said its focus is still on China, where an estimated 10 million people could potentially be exposed to hepatitis C.
The Chinese market is anticipated to grow as local cities step up diagnostic and treatment efforts, the company said.
TaiGen shares have risen 0.23 percent this year, closing at NT$21.75 on Friday, lower than the biotech sub-index, which has gained 13.26 percent over the period.
Taiwan’s technology protection rules prohibits Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) from producing 2-nanometer chips abroad, so the company must keep its most cutting-edge technology at home, Minister of Economic Affairs J.W. Kuo (郭智輝) said yesterday. Kuo made the remarks in response to concerns that TSMC might be forced to produce advanced 2-nanometer chips at its fabs in Arizona ahead of schedule after former US president Donald Trump was re-elected as the next US president on Tuesday. “Since Taiwan has related regulations to protect its own technologies, TSMC cannot produce 2-nanometer chips overseas currently,” Kuo said at a meeting of the legislature’s
GEOPOLITICAL ISSUES? The economics ministry said that political factors should not affect supply chains linking global satellite firms and Taiwanese manufacturers Elon Musk’s Space Exploration Technologies Corp (SpaceX) asked Taiwanese suppliers to transfer manufacturing out of Taiwan, leading to some relocating portions of their supply chain, according to sources employed by and close to the equipment makers and corporate documents. A source at a company that is one of the numerous subcontractors that provide components for SpaceX’s Starlink satellite Internet products said that SpaceX asked their manufacturers to produce outside of Taiwan because of geopolitical risks, pushing at least one to move production to Vietnam. A second source who collaborates with Taiwanese satellite component makers in the nation said that suppliers were directly
Top Taiwanese officials yesterday moved to ease concern about the potential fallout of Donald Trump’s return to the White House, making a case that the technology restrictions promised by the former US president against China would outweigh the risks to the island. The prospect of Trump’s victory in this week’s election is a worry for Taipei given the Republican nominee in the past cast doubt over the US commitment to defend it from Beijing. But other policies championed by Trump toward China hold some appeal for Taiwan. National Development Council Minister Paul Liu (劉鏡清) described the proposed technology curbs as potentially having
TALENT FACTOR: The nation’s chip sector would be difficult to replace, but to maintain that advantage, Taiwan must retain skilled workers, an academic said A group of experts on Sunday called on Taiwan to strive to maintain its world-leading position in the semiconductor industry, with a US-China chip dispute expected to continue regardless of who becomes the next US president. Tamkang University Graduate Institute of International Affairs and Strategic Studies director Li Da-jung (李大中) said at a Taipei seminar on global semiconductor security that the relationship between the two superpowers would remain confrontational. There appears to be “no turning back” in US-China relations, as US presidential candidates US Vice President Kamala Harris and former US president Donald Trump are both expected to continue Washington’s hawkish stance
RSS